- Asymchem has implemented a fully automated system to scale up peptide drug production.
- The technology integrates advanced simulation, control systems, and a new patent-pending synthesizer design.
Asymchem has reached a new milestone in pharmaceutical contract manufacturing with the introduction of fully automated, large-scale peptide drug production. This achievement, accomplished through advanced engineering and system integration, addresses several industry challenges in scaling up chemical macromolecule synthesis.
Asymchem’s breakthrough follows extensive development led by its Chemical Engineering Department (CED) and Center for Intelligent Manufacturing Technology (CIMT). A key development was the design of a new solid-phase synthesizer that overcomes limitations in scaling, optimising both resin mixing and reactor structure. The new synthesizer, currently under patent application, is expected to support production volumes of up to 2,000 litres.
To achieve a fully automated workflow, Asymchem integrated multiple systems to facilitate continuous, unmanned production. The CED developed a constant-pressure solvent delivery system, ensuring that solvent transfers are automatically managed by a Distributed Control System (DCS). The company also implemented an automated formulation system, which coordinates between utility and production systems to streamline resource availability and waste management.
“This advancement highlights our commitment to providing scalable solutions that meet the increasing demand for peptide drugs,” an Asymchem representative stated. “Our new systems eliminate traditional production bottlenecks, enhancing capacity and consistency across our facilities.”
Asymchem’s automated peptide synthesis now supports production volumes exceeding 10,000 litres, with multiple lines validated and transitioning to commercial technology transfer.
Overview of outsourcing trends 
